REG - Oxford Biomedica PLC - Oxford Biomedica Solutions signs new partner

Oxford BioMedicaAnnouncement

14/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220914:nRSN3578Za&default-theme=true

RNS Number : 3578Z  Oxford Biomedica PLC  14 September 2022

 

Oxford Biomedica Solutions signs agreement with new partner for AAV platform

Oxford, UK - 14 September 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces that its subsidiary Oxford Biomedica Solutions LLC ("Oxford
Biomedica Solutions"), a high-performing full-scope scope AAV manufacturing
and innovation business, has signed an agreement with a new undisclosed, U.S.
based, private biotechnology company. The agreement grants the partner access
to Oxford Biomedica Solutions' process and manufacturing platform, and "The
Full Solution" service offering, with end-to-end capabilities for their
pre-clinical gene therapy programmes.

 

Under the terms of the agreement, Oxford Biomedica Solutions will receive
payments relating to the full scope of process development, from construct
design through to toxicology manufacturing for the partner's programmes.

 

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: "We
are delighted to announce this new AAV partnership, and look forward to
offering Oxford Biomedica Solutions' full-scope platform to our new partner
and supporting them with their construct design and product development needs.
This agreement marks a very important step towards achieving our strategic
objective of becoming a global viral vector leader across all key vector
types, delivering life changing therapies to patients."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, VP, Corporate Affairs and Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a US based subsidiary AAV manufacturing and innovation business,
based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXXLLFLKLBBBX